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Abstract
Background: While we have international guidelines and various national guidelines for asthma
diagnosis and management, asthma remains poorly controlled in many children and adults. In this
paper we review the limitations of current asthma guidelines and describe important issues and
remaining questions regarding asthma guidelines for use, particularly in primary care.
Discussion: Clinical practice guidelines based on evidence from randomized controlled trials are
considered the most rigorous and accurate. Current evidence-based guidelines are written
predominantly from the perspective of the patient with a clear-cut asthma diagnosis, however, and
tend not to consider the heterogeneity of asthma or to accommodate individual patient variations
in response to treatment or their needs, differences in practice settings, or local differences in
availability and cost of therapies. The results of randomized controlled trials, which are designed
to establish efficacy of treatment under ideal conditions, may not apply to 'real-world' clinical
practice, where patients are unselected, monitoring is less frequent, and effectiveness – the benefit
of treatment in routine clinical practice – is the most relevant outcome. Moreover, most guidelines
see asthma in isolation rather than considering other factors that may impact on asthma and
response to asthma therapy, particularly age, allergic rhinitis, cigarette smoking, adherence, and
genetic factors. When these links are recognized, guidelines rarely provide practical
recommendations for treatment in these scenarios. Finally, there is some evidence that general
practitioners are not convinced of the applicability of asthma guidelines to their practice settings,
especially when those writing the guidelines principally work in specialist practice.
Conclusion: Developing country-specific guidelines or, ideally, local guidelines could provide
more practical solutions for asthma care and could account for regional factors that influence
patient choice and adherence to therapy. Pragmatic clinical trials and well-designed observational
trials are needed in addition to randomized controlled trials to assess real-world effectiveness of
therapies, and such evidence needs also to be considered by guideline writers. Finally, practical
tools to facilitate the diagnosis and assessment of asthma and factors responsible for poor control,
such as associated allergic rhinitis, limited adherence, and smoking behavior, are needed to
supplement treatment information provided in clinical practice guidelines for asthma.
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Background
Asthma is estimated to affect 300 million people world-
wide, with an expected increase to 400 million worldwide
by 2025 [1,2]. A chronic inflammatory disease of the air-
ways, asthma causes 0.25 million deaths annually and
substantial socioeconomic burden around the globe [1,2].
Moreover, despite the development and dissemination in
recent years of both international guidelines and various
national guidelines for asthma diagnosis and manage-
ment, there is evidence that asthma is frequently not well
controlled in many children and adults [3-5]. In this
paper we review the limitations of current asthma guide-
lines and describe important issues and remaining ques-
tions regarding asthma guidelines for use in primary care
practice.
Overview of current guidelines
The systematic establishment of a thorough evidence base
is currently considered the most rigorous and accurate
means to develop clinical practice guidelines [6,7]. Devel-
oping evidence-based consensus guidelines is an enor-
mous undertaking in a field such as asthma, involving a
major literature search, consideration of thousands of
papers, and time commitment by numerous individuals
in the respiratory medical community. Several hierarchies
of evidence and grading recommendations have been
used by different working groups [6-8]; those used by the
Scottish Intercollegiate Guidelines Network are presented
in Table 1. The Grades of Recommendation Assessment,
Development and Evaluation Working Group has
recently proposed a system for grading quality of evidence
and strength of recommendations that can be applied
across a wide range of interventions and contexts [7].
The Global Initiative for Asthma (GINA) was first
launched in 1993 as a program to reduce asthma preva-
lence, morbidity, and mortality in collaboration with the
World Health Organization and the National Heart, Lung,
and Blood Institute of the National Institutes of Health in
the United States. GINA has published evidence-based
asthma guidelines since 2002 [9]; annual updates are
available on the GINA website [10]. These guidelines
emphasize the fact that asthma is a chronic inflammatory
disorder of the airways and that, while asthma exacerba-
tions are episodic, airway inflammation is chronically
present [10]. Exposure to allergens is listed as a common
risk factor. The fact that medication must be taken every
day by most patients to control symptoms, to improve
lung function, and to prevent attacks is noted. Criteria
defining the control of asthma are presented in the guide-
lines (Table 2). Moreover, the guidelines provide criteria
for determining asthma severity; and recommendations
Table 1: Hierarchy of levels of evidence from published papers, and grades of recommendation based on this hierarchy, as used by the 
Scottish Intercollegiate Guidelines Network [6]
Hierarchy of levels of evidence from published papers
1++ High quality meta-analyses, systematic reviews of randomized controlled trials (RCTs), or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias
2++ High quality systematic reviews of case control or cohort studies
High quality case control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the 
relationship is causal
2+ Well conducted case control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the 
relationship is causal
2- Case control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal
3 Non-analytic studies, eg, case reports, case series
4 Expert opinion
Grades of recommendation
A At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population, or
A systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+, directly applicable to the target 
population and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target population and demonstrating overall consistency of 
results, or
Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of 
results, or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4, or
Extrapolated evidence from studies rated as 2+
Reprinted with permission from the Scottish Intercollegiate Guidelines Network (SIGN) [6].BMC Pulmonary Medicine 2006, 6(Suppl 1):S6
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for pharmacological management of asthma are outlined
according to a stepwise approach based on asthma sever-
ity.
Other examples of English-language, strict evidence-based
guidelines are the British Asthma Guidelines, which were
revised most recently in November 2005 and are available
on the Scottish Intercollegiate Guidelines Network web-
site [11], and the Canadian Consensus Asthma Guidelines
[12], which are pragmatic, evidence-based guidelines
based on the same hierarchy of evidence as the British
guidelines and were last revised in 2003 [13,14]. The
International Primary Care Airways Group more recently
developed a handbook to guide primary care physicians
in the management of chronic airways disease [15]. This
handbook provides an algorithmic approach to differen-
tial diagnosis of allergic rhinitis, asthma, and chronic
obstructive pulmonary disease using validated question-
naires and diagnostic guides that are consistent with evi-
dence-based guidelines developed by GINA, by the Global
Initiative for Chronic Obstructive Lung Disease, and by
the Allergic Rhinitis and its Impact on Asthma (ARIA) ini-
tiative. In addition, guidelines for the diagnosis of respira-
tory disease and treatment of allergic rhinitis have been
published by the International Primary Care Respiratory
Group [16,17].
Limitations of current guidelines
Clinical practice guidelines are by their nature general rec-
ommendations aimed for broad applicability in the clini-
cal setting. Applicability, however, is limited by several
factors. One of the challenges to the daily use of current
asthma guidelines by physicians is that these guidelines
tend to be disease-oriented, not patient-oriented. Guide-
lines are written not from the perspective of the patient
who comes to the physician's office with symptoms, but
rather from the perspective of the patient with a clear-cut
asthma diagnosis. Symptom-based guidelines are needed
[2]. In addition, there are patients who do not fit within
many current guideline definitions; for example, children
with intermittent wheezing that does not appear to be the
classical asthmatic phenotype [18]. Moreover, guideline
recommendations tend to be based on disease severity
without accounting for concomitant conditions, such as
allergic rhinitis, or the time course of disease – factors
used by clinicians to individualize the diagnosis and the
treatment plan.
In addition, clinical practice guidelines for asthma tend
not to consider the heterogeneity of asthma or to accom-
modate individual patient variations in response to treat-
ment or their needs, differences in practice settings, or
local differences in availability and cost of therapies.
Guideline recommendations are generally made on the
basis of grouped mean data, and fail to recognize individ-
ual heterogeneity. For instance, a recent crossover trial
comparing an inhaled corticosteroid with a leukotriene
receptor antagonist for the treatment of persistent child-
hood asthma found that, while both treatments were
effective, on average the effect was greater in those treated
with inhaled corticosteroid. When individual patient
responses on each treatment were compared, however,
29% of children had better asthma control (asthma con-
trol days/week) on the leukotriene receptor antagonist,
indicating that for this subgroup the leukotriene receptor
antagonist would be the ideal monotherapy [19].
Asthma is most commonly managed in the community in
general practice settings, and the organization of medical
care will affect how asthma care can be delivered. Differ-
ential diagnoses vary according to location, with infec-
tious disease being more common in less developed
countries. Moreover, currently available guidelines are
based on the assumption that the recommended drugs are
available and affordable [2], an assumption that is not
true in many parts of the world. There is therefore a press-
ing need for local guidelines [8]. To be useful to primary
care physicians, these guidelines must be in the local lan-
guage as well as physically available, whether by Internet
or in print.
Limitations of the evidence-based approach
The results of well-designed randomized controlled trials
(RCTs) and meta-analyses of RCTs are awarded the high-
est level of evidence in hierarchies of evidence-based data
collection used to formulate clinical practice guidelines
[6,8]. RCTs, however, are designed to maximize internal
validity and to minimize confounding factors by studying
a tightly defined population in a controlled setting, and
therefore to establish the efficacy of treatment; namely, the
benefit of the treatment under ideal conditions. RCTs are
not primarily concerned with the external validity or gen-
eralizability of the findings to whole populations, and dif-
ferences between the homogeneity of the trial population
and the heterogeneity of the general population labeled as
having asthma may limit the generalizability of RCT find-
ings [20]. These trials generally enroll a carefully selected
Table 2: Asthma control as defined by the Global Initiative for 
Asthma guidelines [10]
Minimal (ideally no) chronic symptoms, including nocturnal symptoms
Minimal (infrequent) exacerbations
No emergency visits
Minimal (ideally no) need for p.r.n. (as-needed) β2-agonist
No limitations on activities, including exercise
PEF circadian variation of less than 20%
(Near) Normal PEF
Minimal (or no) adverse effects from medicine
PEF, peak expiratory flow.BMC Pulmonary Medicine 2006, 6(Suppl 1):S6
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patient population meeting strict inclusion criteria and
exclusion criteria, involve frequent clinical and laboratory
monitoring, and measure objective parameters of efficacy.
In 'real-world' clinical practice, however, patients are
unselected, monitoring tends to be less frequent and less
complete, and effectiveness  – the benefit that treatment
produces in routine clinical practice [21] – is the most rel-
evant outcome.
Herland and coworkers [22] found that only 5.4% of out-
patients with asthma recruited at 12 centers in their study
would have qualified for enrollment in a classical RCT. If
patients with symptoms or patients who regularly used
inhaled corticosteroids were also excluded, as they are in
some RCTs, the percentage fell to 3.3% of asthma outpa-
tients. The patients entering RCTs are therefore not repre-
sentative of asthma patients in primary care [22].
Moreover, the frequent clinical care and monitoring of
patients in RCTs is not typical of 'real-world' clinical situ-
ations and thus the outcomes of the RCTs may not be
attainable in 'real-world' clinical situations. Finally, meas-
ures of airway obstruction do not correlate with patient-
reported measures, and it is therefore important to assess
at least one endpoint from each of these categories in clin-
ical trials [20,23,24].
Information gained from pragmatic trials and observa-
tional studies can be a valuable adjunct to that gained by
RCTs. Pragmatic trials, which may be blinded or open
label, are designed to more closely replicate conditions in
clinical practice, including variability in patient character-
istics and the use of a management protocol rather than a
predetermined assigned treatment [21]. Observational
studies are valuable to examine large groups of patients, to
examine long-term outcomes, to examine rare but impor-
tant outcomes such as mortality, and to examine out-
comes that may not be easily assessed in RCTs, such as
pharmacoeconomic data. Recent comparisons of results
obtained by RCTs and by observational studies found that
effects of treatment determined in observational studies
were not systematically greater or qualitatively different
from those of RCTs comparing the same treatments
[25,26]. The reliance on RCTs as the highest level of evi-
dence is therefore being challenged [27]; even regulatory
agencies are now beginning to review evidence from well-
designed observational research when making labeling
evaluations. On the contrary, the quality of design and
reporting of many observational studies has been ques-
tioned [28]. The same attention to design, the control of
confounding factors, and complete reporting are clearly as
necessary for observational studies as for RCTs.
Evidence-based guidelines are further limited by the time
lag involved in the process, typically entailing 1–2 years,
of reviewing the literature, arriving at a consensus, and
actually writing and publishing the guidelines. This allows
for potentially relevant studies to be published but not
assessed. One mechanism for acknowledging more recent
papers might be to provide electronic links to them from
the guidelines, noting that the information they contain
may be relevant but will not be commented on in the
present guidelines.
Lack of accounting for comorbid conditions and 
confounding factors
Most guidelines see asthma in isolation rather than con-
sidering other factors that may impact on asthma and the
response to asthma therapy, particularly allergic rhinitis,
cigarette smoking, adherence to therapy, and genetic fac-
tors.
The association between the upper airways and the lower
airways has been recognized for two millennia: as long
ago as 200 AD, Galen recommended purging the nostrils
of secretions in order to relieve the lungs. In the late nine-
teenth century, Charles Blackley linked hay fever and
asthma [29]. Current evidence for the many pathophysio-
logical and epidemiological links between asthma and
allergic rhinitis is discussed in other papers in the present
supplement [30,31]. In recent clinical guidelines, how-
ever, with the exception of the ARIA guidelines [32], these
links between allergic rhinitis and asthma are not fully
addressed.
The GINA guidelines note that 'special considerations are
required in managing asthma in relation to ... rhinitis';
however, there is no further guidance – such as a recom-
mendation to examine the nose or to ask the patient
whether or how allergic rhinitis worsens their asthma
[10]. Moreover, the guidelines note that treatment of rhin-
itis may improve asthma symptoms, citing results of an
observational study and a review [33,34]. They do not,
however, cover the concept that asthma and allergic rhin-
itis are related conditions linked by one common airway.
Therefore, while the GINA guidelines mention the associ-
ation between asthma and allergic rhinitis, they fall short
of describing practical recommendations for concomitant
treatment. The British asthma guidelines and the Cana-
dian asthma guidelines cited earlier are similarly lacking
in providing advice on concomitant treatment.
The ARIA guidelines [32] were the first to stress the con-
nection between allergic rhinitis and asthma. Since their
publication in 2001 new data have been published that
support these recommendations, as summarized in
another paper in the present supplement [30]. The ARIA
guidelines note that allergic rhinitis should be considered
one of the risk factors for asthma [32]. Moreover, these
guidelines recommend evaluating patients with persistent
allergic rhinitis for asthma and evaluating patients withBMC Pulmonary Medicine 2006, 6(Suppl 1):S6
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asthma for rhinitis. A 'combined strategy' to treat the
upper airways and the lower airways is recommended
[32].
The early evidence indicates that treating allergic rhinitis
may help to control asthma symptoms. A recent post-hoc
evaluation of the Clinical Observation of Montelukast as
a Partner Agent for Complementary Therapy study
showed the benefit of montelukast, a potent leukotriene
receptor antagonist, for patients with coexisting asthma
and rhinitis [35]. Cysteinyl leukotrienes are key mediators
of both allergy and allergic rhinitis [32,36,37]; montelu-
kast, which is approved to treat both asthma and allergic
rhinitis in many parts of the world, has been shown to
improve asthma and allergic rhinitis in patients with both
these conditions [38]. The study enrolled adult patients
with asthma inadequately controlled by inhaled corticos-
teroids; adding montelukast to the therapy was compared
with doubling the inhaled budesonide dose [39]. In the
group of patients receiving the doubled budesonide dose,
patients with coexisting rhinitis did less well than those
without rhinitis; whereas in the montelukast therapy
group, patients with coexisting rhinitis performed as well
as those without rhinitis [35]. These results suggest that
improvements in rhinitis produced by montelukast ther-
apy may be associated with improvements in asthma.
Cigarette smoking is another factor that can adversely
affect asthma control. The prevalence of active smoking
among adults with asthma is similar to that among those
without asthma, tending to be about 25% in developed
countries [40]. Cigarette smoking, both active and pas-
sive, can increase susceptibility to developing asthma in
predisposed individuals [10,40,41]. Moreover, for
patients with asthma, active smoking is associated with
more severe asthma symptoms and a more rapid decline
in lung function than for nonsmokers. Of note, active
smokers with asthma tend to be resistant to both oral and
inhaled corticosteroid therapy [40]. Smoking cessation is
therefore an important component of asthma manage-
ment. Recent evidence indicates that lung function
improves and sputum neutrophil counts fall within sev-
eral weeks among patients who quit smoking relative to
those who do not quit [42].
Adherence to therapy and compliance with physician rec-
ommendations are other important components of suc-
cessful asthma management. Many factors contribute to
level of adherence to controller therapy for asthma,
including beliefs about the benefits of treatment, concerns
about potential adverse effects of treatment, perceived
asthma severity, and duration of asthma [43,44]. In addi-
tion, cultural factors may influence beliefs about medica-
tions [45]. Reported factors influencing adherence among
adolescents also include cognitive difficulties, lack of
social support, lack of self-efficacy, denial or distrust, and
peer and family issues [46].
A complete understanding of the goals of asthma therapy
could improve patient adherence to prescribed therapy.
Both physicians and patients often overestimate asthma
control relative to guideline definitions of control; more-
over, patients tend to accept their asthma symptoms and
may consider their asthma better controlled than their
physicians do [3,4,47]. A better awareness of guideline
definitions should therefore be promoted: patients and
their families need to understand the nature of asthma
symptoms and, most importantly, the criteria defining
asthma control.
Finally, as a better understanding is gained of the genetic
factors controlling asthma phenotypes, this information
should be included in asthma guidelines. Genetic factors
are important in determining responders and nonre-
sponders to specific treatments for asthma. For example,
patients with aspirin-intolerant asthma show upregula-
tion of leukotriene C4 synthase and excess leukotriene
production, with responsiveness to leukotriene receptor
antagonist therapy [48,49]. A single nucleotide polymor-
phism (allelic variant C of leukotriene C4 synthase) has
been identified that shows moderate association with
aspirin-intolerant asthma [48]. Polymorphisms of the
gene encoding the β2-adrenergic receptor (ADRB2) appear
to play a role in bronchodilator responsiveness and con-
stitute an area of active research [50], the results of which
should be reflected in future guidelines.
Practical tools to assess symptoms and asthma 
control
Simple questionnaires to assess the presence of asthma
and rhinitis symptoms have been proposed in the new
International Primary Care Respiratory Group guidelines
for the diagnosis of respiratory diseases in primary care
[17] (displayed in Tables 3 and 4). Moreover, tools to
readily estimate the impairment and impact on quality of
life associated with allergic rhinitis and asthma would
help healthcare providers to individualize therapy. Many
patients consulting general practitioners for allergic rhini-
tis have substantial impairment in quality of life, sleep,
daily activities, and work performance [51].
A practical tool to assess asthma control, the 6-Point
Asthma and Allergic Rhinitis Status Measure, has been
developed by the General Practice Airways Group with
Allergy UK, and is available for download from the Gen-
eral Practice Airways Group website [52]. This short sur-
vey includes questions about smoking and the presence of
allergic rhinitis symptoms. Suggestions of possible reme-
dies to improve asthma control, as guided by question-
naire results, are provided for the physician. Moreover,BMC Pulmonary Medicine 2006, 6(Suppl 1):S6
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assessment of the actual use of prescribed controller med-
ication (adherence) and assessment of inhaler techniques
are noted as important evaluations guiding the decision-
making process.
Adherence to guidelines by physicians in 
practice
Guideline recommendations are only as successful as are
the human individuals – the healthcare providers and the
patients – in applying them in clinical practice. Primary
care physicians often do not follow guidelines [47,53-55].
There is some evidence that general practitioners are not
convinced of the applicability of guidelines to their prac-
tice settings and that they perceive a tension between pri-
mary and secondary care [55]. Guidelines for use in
primary care are often written by specialists. Reported bar-
riers to guideline use in primary care vary according to the
setting, and include lack of awareness, lack of familiarity,
or lack of agreement, as well as lack of self-efficacy, lack of
outcome expectancy, inertia of previous practice, and time
limitations; external barriers related to guideline factors,
patient factors, and environmental factors are also
reported [53,56]. For guidelines to be effective, they
clearly must be accessible and perceived by the primary
care community as relevant to daily clinical practice.
Conclusion
Practice guidelines are more likely to be followed if they
are simple and flexible [57]. The development of country-
specific guidelines or, ideally, local guidelines for each
region would provide more practical solutions for asthma
care and would account for factors, such as social factors
and costs, that influence patient choice and adherence to
therapy. Pragmatic clinical trials and well-designed obser-
vational trials are needed to provide information on the
effectiveness of therapies in real-world settings. Finally,
practical tools to facilitate the diagnosis and assessment of
asthma and factors responsible for poor control, such as
associated allergic rhinitis, limited adherence, and smok-
ing behavior, are needed to supplement treatment infor-
mation provided in clinical practice guidelines for
asthma.
Table 3: Adult asthma questionnaire
1. Have you had wheezing or whistling in your chest at any time in the last 12 months?
2. Have you been woken up at night by an attack of coughing at any time in the last 12 months?
3. Have you been woken up at night by an attack of shortness of breath at any time in the last 12 months?
4. Have you woken up with a feeling of tightness in your chest at any time in the last 12 months?
If new or recurrent asthma or rhinitis is suspected, assess possible occupational association.
5. Do your symptoms occur less frequently or not at all on days away from work and on vacations?
If yes, ask about the nature of the patient's occupation and consider 4-hourly peak flow recording at and away from work and consider referring patient to a 
specialist for further assessment.
NOTE: Any patient diagnosed with asthma should also be evaluated for allergic rhinitis.
Reprinted with permission from Levy and coworkers [17].
Table 4: Allergic rhinitis questionnaire
1. Do you have any of the following symptoms:*
•Symptoms on only one side of your nose
•Nasal obstruction without other symptoms
•Thick, green or yellow discharge from your nose
•Postnasal drip (down the back of your throat) with thick mucus and/or no runny nose
•Facial pain
•Recurrent nosebleeds
•Inability to smell
2. Do you have any of the following symptoms for at least 1 hour on most days (or on most days during the season if your symptoms are 
seasonal)?†
•Watery runny nose
•Sneezing, especially violent and in bouts
•Nasal obstruction
•Nasal itching
•Conjunctivitis (red, itchy eyes)
*These symptoms are usually NOT found in allergic rhinitis and the presence of ANY ONE of them suggests that alternative diagnoses should be 
investigated.
†Scoring System: The presence of watery runny nose with ONE OR MORE of the other symptoms in this list suggests allergic rhinitis, and indicates that the 
patient should undergo further diagnostic assessment.
NOTE: Any patient diagnosed with allergic rhinitis should also be evaluated for asthma.
Reprinted with permission from Levy and coworkers [17].BMC Pulmonary Medicine 2006, 6(Suppl 1):S6
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